Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Nov:29:139-141.
doi: 10.1016/j.jdcr.2022.09.009. Epub 2022 Sep 20.

Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept

Rachel Choi  1 , James Garritano  1 , Mary Laird  1 , Margaret Johnston  1 , Elizabeth Tkachenko  1 , William Damsky  1 , Alicia J Little  1 , Jennifer McNiff  1   2 , Michael Girardi  1 , Caroline A Nelson  1
Affiliations
Case Reports

Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept

Rachel Choi et al. JAAD Case Rep. 2022 Nov.
No abstract available

Keywords: COVID-19; SJS, Stevens Johnson syndrome; Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; cHIS, COVID-19-associated hyperinflammatory syndrome; etanercept; hyperinflammation; toxic epidermal necrolysis.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Clinical findings. Coalescing red papules on the anterior chest (A) with a positive Nikolsky sign on the right upper back (B), both on initial presentation (day 1). Coalescing red macules and patches with >95% BSA with multiple large flaccid bullae and erosions, demonstrated on the anterior chest on day 2 (C). Significant re-epithelialization after 2 doses of etanercept as demonstrated on the anterior chest on day 11 (D). BSA, Body surface area.
Fig 2
Fig 2
Histopathological findings. Acute basket-woven stratum corneum, widespread, confluent keratinocyte necrosis with focal adnexal involvement, and modest inflammation, seen at 2× (A) and 200× (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Fouchard N., Bertocchi M., Roujeau J.-C., Revuz J., Wolkenstein P., Bastuji-Garin S. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–153. - PubMed
    1. Noe M.H., Rosenbach M., Hubbard R.A., et al. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome/toxic epidermal necrolysis—ABCD-10. JAMA Dermatol. 2019;155:448–454. - PMC - PubMed
    1. Webb B.J., Peltan I.D., Jensen P., et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2020;2:e754–e763. - PMC - PubMed
    1. Zimmerman D., Dang N.H. In: Oncologic Critical Care. Nates J., Price K., editors. Springer; Cham: 2019. Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) - DOI
    1. Jacobsen A., Olabi B., Langley A., et al. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev. 2022;3(3):CD013130. - PMC - PubMed

Publication types

LinkOut - more resources